Review Article
Transplantation of Encapsulated Pancreatic Islets as a Treatment for Patients with Type 1 Diabetes Mellitus
Table 3
Encapsulated islet transplantation in patients with T1DM.
| | Investigator or company | Type of encapsulation | Islet source
(patient number) | Immunosuppression | Transplant site |
| | Soon-Shiong et al. [15] | A-PLL microcapsule | Allogeneic
(1) | Yes, after kidney transplantation | Peritoneal cavity | | Scharp et al. [16] | PAN-PVC diffusion chamber | Allogeneic
(9) | No | Subcutaneous site | | Calafiore et al. [17] | A-PLO microcapsule | Allogeneic
(4) | No | Peritoneal cavity | | Tuch et al. [18] | -alginate microbeads | Allogeneic
(4) | No | Peritoneal cavity | | Amcyte, Inc. | A-PLL microcapsule | Allogeneic
(12 intended) | No | Peritoneal cavity | | Novocell, Inc. (ViaCyte, Inc.) | PEG conformal coating | Allogeneic
(12 intended) | No | Peritoneal cavity | | Living Cell Technologies (LCT) | A-PLO microcapsule | Porcine insulin-producing cells
(DIABECEL) | No | Peritoneal cavity | | Jacobs-Tulleneers-Thevissen et al. [19] | /-alginate microbeads | Allogeneic
(1) | No | Peritoneal cavity | | Sernova Corp. | Macroencapsulation Cell Pouch System | Allogeneic
(under preparation) | NR | Subcutaneous site |
|
|
A-PLL: alginate-polylysine-alginate microcapsule.
PAN-PVC: polyacrylonitrile-polyvinyl chloride.
A-PLO: alginate-polyornitine-alginate microcapsule.
NR: not reported.
PEG: poly(ethylene glycol).
|
